We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues
Read MoreHide Full Article
DexCom Inc. (DXCM - Free Report) reported loss of 9 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 10 cents. DexCom had reported earnings of two cents in the year-ago quarter.
In the reported quarter, total revenue grew to $171.2 million, reflecting an increase of 31% from $130.8 million in the year-ago quarter. This also came in higher than the Zacks Consensus Estimate of $168.0 million.
Stock Performance
The price performance of the stock has been favorable in the last three months. DexCom registered a stable return of 25.74%, outpacing the Zacks classified Medical - Instruments sub-industry’s gain of almost 10.73%.
Operational Details
In the reported quarter, cost of sales increased to $54.5 from $39.6 million in fourth-quarter 2015. This was primarily due to an increase in sales volume.
Research and development expense increased to $29.0 million in the year-ago quarter to $44.0 million. The decrease in research and development expense was primarily due to the absence of a non-cash charge related to Verily Collaboration Agreement incurred in 2015. This was partially offset by additional payroll costs and additional non-cash share-based compensation.
Selling, general and administrative expense totaled $79 million in the reported quarter compared with $61 million during the same quarter in 2015. The rise was primarily due to year-over-year increases in head count in customer support organizations, higher marketing expenses and IT cost.
In the reported quarter, gross profit totaled $117 million, generating a gross margin of 68% compared with a gross profit of $91 million and a gross margin of 70% for the same quarter in the prior year. On a year-over-year basis, gross margin was negatively impacted by sales of G5 Mobile transmitter.
Financial Condition
As of Dec 31, 2016, DexCom had $123.7 million in cash, cash equivalents and short-term marketable securities versus $115.2 million as of Dec 31, 2015.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 184.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock added 1.23% over the last three months.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues
DexCom Inc. (DXCM - Free Report) reported loss of 9 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 10 cents. DexCom had reported earnings of two cents in the year-ago quarter.
In the reported quarter, total revenue grew to $171.2 million, reflecting an increase of 31% from $130.8 million in the year-ago quarter. This also came in higher than the Zacks Consensus Estimate of $168.0 million.
Stock Performance
The price performance of the stock has been favorable in the last three months. DexCom registered a stable return of 25.74%, outpacing the Zacks classified Medical - Instruments sub-industry’s gain of almost 10.73%.
Operational Details
In the reported quarter, cost of sales increased to $54.5 from $39.6 million in fourth-quarter 2015. This was primarily due to an increase in sales volume.
Research and development expense increased to $29.0 million in the year-ago quarter to $44.0 million. The decrease in research and development expense was primarily due to the absence of a non-cash charge related to Verily Collaboration Agreement incurred in 2015. This was partially offset by additional payroll costs and additional non-cash share-based compensation.
Selling, general and administrative expense totaled $79 million in the reported quarter compared with $61 million during the same quarter in 2015. The rise was primarily due to year-over-year increases in head count in customer support organizations, higher marketing expenses and IT cost.
In the reported quarter, gross profit totaled $117 million, generating a gross margin of 68% compared with a gross profit of $91 million and a gross margin of 70% for the same quarter in the prior year. On a year-over-year basis, gross margin was negatively impacted by sales of G5 Mobile transmitter.
Financial Condition
As of Dec 31, 2016, DexCom had $123.7 million in cash, cash equivalents and short-term marketable securities versus $115.2 million as of Dec 31, 2015.
DexCom, Inc. Price, Consensus and EPS Surprise
DexCom, Inc. Price, Consensus and EPS Surprise | DexCom, Inc. Quote
Zacks Rank & Key Picks
Currently, DexCom carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Glaukos Corporation (GKOS - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, all the stocks carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 184.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock added 1.23% over the last three months.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>